ArticleInternational journal of nanomedicine2025
Quantifying Nanoplastic Toxicity Using Gold-Core Polystyrene Nanoparticles: In vivo Evaluation and Human Risk Extrapolation.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Nanoplastics (NPs) are widespread environmental pollutants that pose risks to human health; however, risk thresholds for NPs accumulation in human tissues remain poorly defined. This study validates gold-core polystyrene nanoplastics (AuPS-NPs) as a quantifiable proxy for polystyrene nanoplastics (PS-NPs) to evaluate toxicity and bioaccumulation at environmentally relevant concentrations, with extrapolation to human health implications. Methods: AuPS-NPs were synthesized with a gold core and polystyrene shell, characterized by transmission electron microscopy (TEM) and quantified by inductively coupled plasma mass spectrometry (ICP-MS). In vitro, human gastric adenocarcinoma (AGS) and human colorectal adenocarcinoma (Caco-2) cells were exposed to AuPS-NPs or PS-NPs to assess cytotoxicity, reactive oxygen species generation, and mitochondrial membrane depolarization. In vivo, BALB/c mice were orally exposed to AuPS-NPs (1 and 10 mg/L) for 98 days, followed by evaluation of intestinal accumulation, body weight, organ indices, and biomarkers of inflammation, lipid metabolism, energy metabolism, and oxidative stress. A toxicokinetic-toxicodynamic (TK-TD) model was developed to simulate NPs accumulation, dose-response relationships, and human risk thresholds. Results: AuPS-NPs and PS-NPs showed comparable concentration-dependent cytotoxicity in vitro. In vivo, chronic AuPS-NP exposure caused intestinal accumulation, body weight reduction, increased organ indices, and biomarker perturbations including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), triglycerides (TG), total cholesterol (T-CHO), adenosine triphosphate (ATP), lactate dehydrogenase (LDH), malondialdehyde (MDA), and superoxide dismutase (SOD). TK-TD modeling yielded a human intestinal toxicity threshold of 9.529 × 10 Conclusion: AuPS-NPs replicate PS-NPs toxicity and enable quantitative risk assessment. Chronic exposure may induce intestinal accumulation and systemic toxicity, underscoring the need for regulatory thresholds to mitigate nanoplastic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.